2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Ragan Paula | CEO | 3,337,386 | Feb 14, 2025 |
| Craig Adam R | Chair | 2,329,154 | Oct 31, 2025 |
| Volpone John | — | 2,329,154 | Oct 31, 2025 |
| Chang Carmen | — | 2,000,000 | Jul 17, 2018 |
| Behbahani Ali | — | 2,000,000 | Jul 17, 2018 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 1, 2026 | Jan 7, 2026 | Bridger Gary | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 1, 2026 | Jan 5, 2026 | de Craecker Francoise | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 1, 2026 | Jan 5, 2026 | WYZGA MICHAEL S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 1, 2026 | Jan 5, 2026 | Stewart Murray | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 29, 2025 | Oct 31, 2025 | Craig Adam R | Chair | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 29, 2025 | Oct 31, 2025 | Volpone John | President | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 29, 2025 | Oct 31, 2025 | KIRSKE DAVID | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 23, 2025 | Oct 27, 2025 | Craig Adam R | Chair | Buy | 95.0 | +86,206 | 29.74% | ✗ | $250K |
| Aug 14, 2025 | Aug 14, 2025 | Volpone John | President | Neutral | 90.0 | +289,881 | 100.00% | ✗ | - |
| Aug 14, 2025 | Craig Adam R | Chair | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 14, 2025 | KIRSKE DAVID | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 14, 2025 | Aug 14, 2025 | Craig Adam R | Chair | Neutral | 90.0 | +289,881 | 100.00% | ✗ | - |
| Aug 14, 2025 | Aug 14, 2025 | KIRSKE DAVID | CFO | Neutral | 90.0 | +193,254 | 100.00% | ✗ | - |
| Aug 14, 2025 | Volpone John | President | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 20, 2025 | Jul 3, 2025 | Thoren Natasha Fay | Chief Legal Officer | Neutral | 90.0 | +3,333 | 54.38% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | Stewart Murray | Director | Neutral | 90.0 | +1,500 | 23.50% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | de Craecker Francoise | Director | Neutral | 90.0 | +1,500 | 46.55% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | Bridger Gary | Director | Neutral | 90.0 | +1,500 | 46.55% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | Woods Keith | Director | Neutral | 90.0 | +1,500 | 33.33% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | MCGIRR DAVID W J | Director | Neutral | 90.0 | +1,500 | 46.55% | ✗ | - |
| Jun 9, 2025 | Jun 10, 2025 | WYZGA MICHAEL S | Director | Neutral | 90.0 | +1,500 | 36.99% | ✗ | - |
| Jun 3, 2025 | Thoren Natasha Fay | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 16, 2025 | Jun 3, 2025 | Baldry Mark | Chief Commercial Officer | Neutral | 82.5 | +1,032 | 4.25% | ✗ | - |
| May 16, 2025 | May 20, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 82.5 | +1,032 | 4.25% | ✗ | $2.6K |
| Feb 12, 2025 | Feb 14, 2025 | Arbet-Engels Christophe | Chief Medical Officer | Neutral | 90.0 | +850,000 | 5982.97% | ✗ | - |
| Feb 12, 2025 | Feb 14, 2025 | Mostafa Adam S. | CFO | Neutral | 90.0 | +850,000 | 100.00% | ✗ | - |
| Feb 12, 2025 | Feb 14, 2025 | Ragan Paula | CEO | Neutral | 90.0 | +2,250,000 | 206.92% | ✗ | - |
| May 17, 2024 | Feb 14, 2025 | Baldry Mark | Chief Commercial Officer | Buy | 91.3 | +635,050 | 674.70% | ✗ | $19.3K |
| Feb 12, 2025 | Feb 14, 2025 | DiBiase Mary | COO | Neutral | 90.0 | +650,000 | 132.39% | ✗ | - |
| Jan 23, 2025 | Jan 27, 2025 | Ragan Paula | CEO | Sell | 86.3 | +93,467 | 9.40% | ✓ | $34.7K |
| Jan 23, 2025 | Jan 27, 2025 | Mostafa Adam S. | CFO | Sell | 57.5 | - | 0.00% | ✓ | $33.9K |
| Jan 23, 2025 | Jan 27, 2025 | Baldry Mark | Chief Commercial Officer | Sell | 91.3 | +45,614 | 94.03% | ✓ | $13.2K |
| Jan 23, 2025 | Jan 27, 2025 | DiBiase Mary | COO | Sell | 86.3 | +38,920 | 8.61% | ✓ | $10.1K |
| Jan 23, 2025 | Jan 27, 2025 | Arbet-Engels Christophe | Chief Medical Officer | Sell | 90.0 | +14,207 | 100.00% | ✓ | $5.3K |
| Nov 15, 2024 | Nov 19, 2024 | Ragan Paula | CEO | Sell | 41.3 | -31,897 | -3.11% | ✓ | $12.6K |
| Oct 15, 2024 | Oct 16, 2024 | Ragan Paula | CEO | Sell | 41.3 | -31,897 | -3.02% | ✓ | $17.9K |
| Oct 4, 2024 | Oct 8, 2024 | Mostafa Adam S. | CFO | Sell | 53.8 | - | 0.00% | ✓ | $126.9K |
| Oct 4, 2024 | Oct 8, 2024 | Baldry Mark | Chief Commercial Officer | Sell | 90.0 | +23,819 | 96.47% | ✓ | $6.5K |
| Oct 4, 2024 | Oct 8, 2024 | Ragan Paula | CEO | Sell | 95.0 | +292,645 | 38.25% | ✓ | $131.5K |
| Oct 4, 2024 | Oct 8, 2024 | DiBiase Mary | COO | Sell | 91.3 | +162,950 | 56.36% | ✓ | $38.3K |
| Oct 4, 2024 | Oct 8, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 91.3 | +153,725 | 65.61% | ✓ | $43.3K |
| Sep 9, 2024 | Sep 11, 2024 | DiBiase Mary | COO | Sell | 52.5 | -2,642 | -0.91% | ✓ | $1.7K |
| Jun 10, 2024 | Jun 11, 2024 | de Craecker Francoise | Director | Neutral | 90.0 | +45,000 | 87.10% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Aliski William | Director | Neutral | 90.0 | +45,000 | 87.10% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | MCGIRR DAVID W J | Director | Neutral | 90.0 | +45,000 | 87.10% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Stewart Murray | Director | Neutral | 90.0 | +45,000 | 30.72% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Bridger Gary | Director | Neutral | 90.0 | +45,000 | 87.10% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Woods Keith | Director | Neutral | 90.0 | +45,000 | 50.00% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Lawton Alison Frances | Director | Neutral | 90.0 | +45,000 | 87.10% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | WYZGA MICHAEL S | Director | Neutral | 90.0 | +45,000 | 58.70% | ✗ | - |
| Mar 11, 2024 | Mar 11, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 36.3 | -14,235 | -5.73% | ✓ | $12.6K |
| Mar 11, 2024 | Mar 11, 2024 | Ragan Paula | CEO | Sell | 36.3 | -49,678 | -6.10% | ✓ | $43.9K |
| Mar 11, 2024 | Mar 11, 2024 | Mostafa Adam S. | CFO | Sell | 13.8 | -52,500 | -100.00% | ✓ | $46.3K |
| Mar 11, 2024 | Mar 11, 2024 | DiBiase Mary | COO | Sell | 36.3 | -15,409 | -5.02% | ✓ | $13.6K |
| Feb 13, 2024 | Feb 28, 2024 | Arbet-Engels Christophe | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Arbet-Engels Christophe | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Mostafa Adam S. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | DiBiase Mary | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Ragan Paula | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Baldry Mark | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Taveras Arthur | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 12, 2024 | Feb 12, 2024 | DiBiase Mary | COO | Sell | 50.0 | -3,683 | -1.18% | ✓ | $3.7K |
| Feb 12, 2024 | Feb 12, 2024 | Taveras Arthur | Chief Scientific Officer | Sell | 53.8 | -787 | -0.32% | ✓ | $792.7 |
| Feb 12, 2024 | Feb 12, 2024 | Ragan Paula | CEO | Sell | 45.0 | -21,695 | -2.59% | ✓ | $21.9K |
| Feb 12, 2024 | Feb 12, 2024 | Mostafa Adam S. | CFO | Sell | 13.8 | -27,721 | -34.56% | ✓ | $28K |
| Nov 1, 2023 | Nov 3, 2023 | Ragan Paula | CEO | Sell | 15.0 | -239,437 | -22.26% | ✓ | $181.6K |
| Nov 1, 2023 | Nov 3, 2023 | Mostafa Adam S. | CFO | Sell | 10.0 | -230,645 | -74.19% | ✓ | $168.4K |
| Nov 1, 2023 | Nov 3, 2023 | DiBiase Mary | COO | Sell | 23.8 | -67,695 | -17.88% | ✓ | $49.4K |
| Nov 1, 2023 | Nov 3, 2023 | Baldry Mark | Chief Commercial Officer | Sell | 15.0 | -10,257 | -29.35% | ✓ | $7.5K |
| Nov 1, 2023 | Nov 3, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 18.8 | -67,695 | -21.35% | ✓ | $49.4K |
| Oct 31, 2023 | Nov 2, 2023 | Mostafa Adam S. | CFO | Neutral | 90.0 | +230,645 | 287.51% | ✗ | - |
| Oct 31, 2023 | Nov 2, 2023 | Baldry Mark | Chief Commercial Officer | Neutral | 90.0 | +34,947 | 100.00% | ✗ | - |
| Oct 31, 2023 | Nov 2, 2023 | Taveras Arthur | Chief Scientific Officer | Neutral | 90.0 | +230,645 | 267.03% | ✗ | - |
| Oct 31, 2023 | Nov 2, 2023 | Ragan Paula | CEO | Neutral | 90.0 | +532,081 | 97.85% | ✗ | - |
| Oct 31, 2023 | Nov 2, 2023 | DiBiase Mary | COO | Neutral | 90.0 | +230,645 | 155.95% | ✗ | - |
| Oct 16, 2023 | Oct 18, 2023 | Woods Keith | Director | Neutral | 90.0 | +90,000 | 100.00% | ✗ | - |
| Oct 18, 2023 | Woods Keith | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 8, 2023 | Sep 12, 2023 | DiBiase Mary | COO | Sell | 50.0 | -2,642 | -1.76% | ✓ | $3.3K |
| Aug 31, 2023 | Sep 5, 2023 | Arbet-Engels Christophe | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 18, 2023 | Aug 22, 2023 | WYZGA MICHAEL S | Director | Buy | 91.3 | +25,000 | 48.39% | ✗ | $29.9K |
| Aug 16, 2023 | Arbet-Engels Christophe | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 9, 2023 | Aug 11, 2023 | Stewart Murray | Interim Chief Medical Officer | Sell | 95.0 | +139,837 | 2097.45% | ✗ | $137.9K |
| Jun 30, 2023 | Jul 5, 2023 | DiBiase Mary | COO | Sell | 53.8 | -464 | -0.31% | ✓ | $877 |
| Jun 30, 2023 | Jul 5, 2023 | Mostafa Adam S. | CFO | Sell | 42.5 | -2,641 | -3.19% | ✓ | $5K |
| Jun 23, 2023 | Jun 26, 2023 | DiBiase Mary | COO | Sell | 52.5 | -857 | -0.56% | ✓ | $1.7K |
| Jun 23, 2023 | Jun 26, 2023 | Mostafa Adam S. | CFO | Sell | 36.3 | -5,417 | -6.14% | ✓ | $10.5K |
| Jun 23, 2023 | Jun 26, 2023 | Ragan Paula | CEO | Sell | 48.8 | -6,724 | -1.22% | ✓ | $12.9K |
| Jun 15, 2023 | Jun 16, 2023 | DiBiase Mary | COO | Sell | 52.5 | -857 | -0.56% | ✓ | $1.9K |
| Jun 15, 2023 | Jun 16, 2023 | Mostafa Adam S. | CFO | Sell | 36.3 | -5,417 | -5.78% | ✓ | $12K |
| Jun 15, 2023 | Jun 16, 2023 | Ragan Paula | CEO | Sell | 48.8 | -6,724 | -1.21% | ✓ | $15K |
| Jun 13, 2023 | Jun 14, 2023 | Aliski William | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| Jun 13, 2023 | Jun 14, 2023 | Bridger Gary | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| Jun 13, 2023 | Jun 14, 2023 | MCGIRR DAVID W J | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| Jun 13, 2023 | Jun 14, 2023 | WYZGA MICHAEL S | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| Jun 13, 2023 | Jun 14, 2023 | de Craecker Francoise | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| Jun 13, 2023 | Jun 14, 2023 | Lawton Alison Frances | Director | Neutral | 90.0 | +45,000 | 674.97% | ✗ | - |
| May 31, 2023 | May 31, 2023 | Ragan Paula | CEO | Sell | 48.8 | -6,292 | -1.12% | ✓ | $12.3K |
| Mar 10, 2023 | Mar 13, 2023 | DiBiase Mary | COO | Sell | 28.8 | -18,192 | -10.64% | ✓ | $15.3K |
| Mar 10, 2023 | Mar 13, 2023 | Mostafa Adam S. | CFO | Sell | 13.8 | -52,500 | -35.91% | ✓ | $44.1K |
| Mar 10, 2023 | Mar 13, 2023 | Taveras Arthur | Chief Scientific Officer | Sell | 23.8 | -16,806 | -16.29% | ✓ | $14.1K |